Merck, a pharmaceutical company, agreed to acquire Caraway Therapeutics, a preclinical biopharmaceutical company, for $610m. “Caraway’s multidisciplinary approach has yielded important progress in evaluating novel mechanisms of modulation of lysosomal function with potential for the treatment of progressive neurodegenerative diseases. We look forward to applying our expertise to build upon this work with the goal of developing much needed disease-modifying therapies for these conditions," George Addona, Merck Senior Vice President.